Table 2. Association between clinicopathologic features and BART miRNAs expression.
| miR-BART1-5p (N = 58) | miR-BART4-5p (N = 39) | miR-BART20-5p (N = 57) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | P | Low | High | P | Low | High | P | |
| Gender | 0.747 | 0.451 | 0.735 | ||||||
| Male | 22 (75.9) | 24 (82.8) | 14 (73.7) | 17 (85.0) | 30 (78.9) | 16 (84.2) | |||
| Female | 7 (24.1) | 5 (17.2) | 5 (26.3) | 3 (15.0) | 8 (21.1) | 3 (15.8) | |||
| Age | 0.058 | 0.882 | 0.336 | ||||||
| < 64 | 7 (24.1) | 15 (51.7) | 9 (47.4) | 9 (45.0) | 13 (34.2) | 9 (84.2) | |||
| ≥ 64 | 22 (75.9) | 14 (48.3) | 10 (52.6) | 11 (55.0) | 25 (65.8) | 10 (15.8) | |||
| T stage | 0.788 | 0.265 | 0.159 | ||||||
| T1/2 | 12 (41.4) | 11 (37.9) | 9 (47.4) | 6 (30.0) | 18 (47.4) | 5 (26.3) | |||
| T3/4 | 17 (58.6) | 18 (62.1) | 10 (52.6) | 14 (70.0) | 20 (52.6) | 14 (73.7) | |||
| LN metastasis | 0.293 | 0.429 | 0.260 | ||||||
| No | 17 (58.6) | 13 (44.8) | 10 (52.6) | 8 (40.0) | 22 (57.9) | 7 (42.1) | |||
| Yes | 12 (41.4) | 16 (55.2) | 9 (47.4) | 12 (60.0) | 16 (42.1) | 11 (57.9) | |||
| WHO classification | 0.588 | 0.651 | 0.847 | ||||||
| GCLS | 12 (41.4) | 10 (34.5) | 7 (36.8) | 6 (30.0) | 15 (39.5) | 7 (36.8) | |||
| Non-GCLS | 17 (58.6) | 19 (65.5) | 12 (63.2) | 14 (70.0) | 23 (60.5) | 12 (63.2) | |||
| Lauren classification | 0.456 | 0.301 | 0.430 | ||||||
| Intestinal | 5 (17.2) | 2 (6.9) | 1 (5.3) | 2 (10.0) | 6 (15.8) | 1 (5.3) | |||
| Diffuse | 22 (75.9) | 24 (82.8) | 14 (73.7) | 17 (85.0) | 30 (78.9) | 16 (84.2) | |||
| Mixed | 2 (6.9) | 3 (10.3) | 4 (21.1) | 1 (5.0) | 2 (5.3) | 2 (10.5) | |||
LN, lymph node metastasis; GCLC, Gastric carcinoma with lymphoid stroma.